10 Best Undervalued Stocks Insiders Are Buying for February 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
In the current market environment, value investors seek stocks trading below their intrinsic value, supported by strong fundamentals like high ROIC, robust free cash flow, and quality ratings from ValueSense analysis. This 10 best stock picks watchlist highlights companies across technology, financials, industrials, healthcare, energy, and transportation sectors, selected using ValueSense's proprietary methodology. Criteria include intrinsic value significantly above implied market price, quality ratings above 5.0 where possible, positive free cash flow generation, and impressive 1Y returns demonstrating momentum. These picks emphasize undervalued stocks with growth potential, drawn exclusively from ValueSense data for educational analysis.
Featured Stock Analysis
Stock #1: Micron Technology, Inc. (MU)
| Metric | Value |
|---|---|
| Market Cap | $486.8B |
| Quality Rating | 8.2 |
| Intrinsic Value | $419.0 |
| 1Y Return | 348.5% |
| Revenue | $42.3B |
| Free Cash Flow | $17.3B |
| Revenue Growth | 45.4% |
| FCF margin | 40.9% |
| Gross margin | 45.3% |
| ROIC | 23.4% |
| Total Debt to Equity | 21.2% |
Investment Thesis
Micron Technology, Inc. (MU) stands out as a top performer in the technology sector with a stellar Quality rating of 8.2, the highest in this watchlist. Its intrinsic value of $419.0 suggests substantial undervaluation, backed by explosive 1Y Return of 348.5% and Revenue of $42.3B growing at 45.4%. Exceptional Free Cash Flow of $17.3B yields a 40.9% FCF margin, complemented by 45.3% Gross margin and 23.4% ROIC. With a manageable Total Debt to Equity of 21.2% and Market Cap of $486.8B, MU exemplifies efficient capital allocation in semiconductors, positioning it for sustained growth in memory and data center demand. This analysis highlights MU's fundamental strength for value-oriented portfolios.
Key Catalysts
- Surge in revenue growth at 45.4%, driven by high-demand tech cycles
- Industry-leading 40.9% FCF margin and $17.3B free cash flow generation
- High ROIC of 23.4% indicating superior capital efficiency
- Massive 348.5% 1Y return signaling strong market momentum
Risk Factors
- Potential cyclical downturns in semiconductor demand
- Vulnerability to global supply chain disruptions
- Competition intensifying in memory chip markets
Stock #2: Intel Corporation (INTC)
| Metric | Value |
|---|---|
| Market Cap | $233.1B |
| Quality Rating | 4.7 |
| Intrinsic Value | $76.4 |
| 1Y Return | 132.2% |
| Revenue | $52.9B |
| Free Cash Flow | ($4,949.0M) |
| Revenue Growth | (0.5%) |
| FCF margin | (9.4%) |
| Gross margin | 35.1% |
| ROIC | (1.2%) |
| Total Debt to Equity | 36.9% |
Investment Thesis
Intel Corporation (INTC) presents a turnaround opportunity in technology with a Market Cap of $233.1B and Quality rating of 4.7. Despite challenges, its intrinsic value of $76.4 points to undervaluation, supported by a robust 132.2% 1Y Return and Revenue of $52.9B. Negative Free Cash Flow of $4,949.0M reflects a -9.4% FCF margin, with slight revenue decline of 0.5%, 35.1% Gross margin, and -1.2% ROIC. Total Debt to Equity at 36.9% remains moderate. This educational analysis underscores INTC's potential recovery through foundry investments and AI chip developments, appealing to patient value investors monitoring fundamental improvements.
Key Catalysts
- Strong 132.2% 1Y return despite operational headwinds
- $52.9B revenue base providing scale for restructuring
- Investments in advanced manufacturing for future growth
- 35.1% gross margin supporting margin expansion potential
Risk Factors
- Persistent negative FCF and -9.4% margin pressuring liquidity
- Declining ROIC at -1.2% signaling efficiency issues
- Intense competition from AMD and TSMC in chips
- Execution risks in strategic pivots
Stock #3: Banco Santander, S.A. (SAN)
| Metric | Value |
|---|---|
| Market Cap | $189.4B |
| Quality Rating | 6.7 |
| Intrinsic Value | $17.3 |
| 1Y Return | 152.5% |
| Revenue | $75.9B |
| Free Cash Flow | $20.1B |
| Revenue Growth | (3.4%) |
| FCF margin | 26.5% |
| Gross margin | 63.0% |
| ROIC | 25.8% |
| Total Debt to Equity | 288.1% |
Investment Thesis
Banco Santander, S.A. (SAN), a global financial powerhouse, boasts a Market Cap of $189.4B and Quality rating of 6.7. Its intrinsic value of $17.3 indicates undervaluation, fueled by 152.5% 1Y Return and massive Revenue of $75.9B. Strong Free Cash Flow of $20.1B delivers 26.5% FCF margin, with 63.0% Gross margin and impressive 25.8% ROIC, though Total Debt to Equity is elevated at 288.1% due to banking leverage. Slight Revenue growth dip of 3.4% is offset by cash generation prowess. This analysis frames SAN as a high-yield banking play for diversified stock watchlist strategies.
Key Catalysts
- Exceptional 152.5% 1Y return highlighting momentum
- $20.1B FCF and 26.5% margin for shareholder returns
- High 25.8% ROIC demonstrating operational excellence
- 63.0% gross margin in competitive banking landscape
Risk Factors
- High 288.1% debt-to-equity from sector norms
- Revenue contraction of 3.4% amid economic pressures
- Interest rate sensitivity impacting net margins
- Geopolitical risks in international operations
Stock #4: The Boeing Company (BA)
| Metric | Value |
|---|---|
| Market Cap | $177.3B |
| Quality Rating | 5.5 |
| Intrinsic Value | $267.8 |
| 1Y Return | 30.2% |
| Revenue | $89.5B |
| Free Cash Flow | $1,492.0M |
| Revenue Growth | 34.5% |
| FCF margin | 1.7% |
| Gross margin | 4.8% |
| ROIC | (5.2%) |
| Total Debt to Equity | 991.4% |
Investment Thesis
The Boeing Company (BA) offers aerospace exposure with Market Cap $177.3B and Quality rating 5.5. Intrinsic value at $267.8 signals deep undervaluation, with 30.2% 1Y Return and Revenue $89.5B surging 34.5%. Modest Free Cash Flow $1,492.0M yields 1.7% FCF margin, low 4.8% Gross margin, and -5.2% ROIC, exacerbated by 991.4% Total Debt to Equity. This ValueSense-driven analysis examines BA's recovery trajectory amid production ramps and order backlogs, suitable for long-term industrial stock picks.
Key Catalysts
- Robust 34.5% revenue growth from commercial aviation rebound
- 30.2% 1Y return amid order backlog expansion
- Strategic focus on defense and space segments
- Improving cash flow trajectory to $1.5B
Risk Factors
- Extreme 991.4% debt-to-equity burden
- Negative ROIC at -5.2% from operational disruptions
- Low 1.7% FCF margin limiting flexibility
- Regulatory and safety scrutiny risks
Stock #5: Pfizer Inc. (PFE)
| Metric | Value |
|---|---|
| Market Cap | $148.9B |
| Quality Rating | 6.0 |
| Intrinsic Value | $46.3 |
| 1Y Return | -1.7% |
| Revenue | $62.8B |
| Free Cash Flow | $10.4B |
| Revenue Growth | 4.4% |
| FCF margin | 16.5% |
| Gross margin | 69.4% |
| ROIC | 9.8% |
| Total Debt to Equity | 66.3% |
Investment Thesis
Pfizer Inc. (PFE) in healthcare shows Market Cap $148.9B and Quality rating 6.0. Intrinsic value $46.3 highlights undervaluation, despite -1.7% 1Y Return, with Revenue $62.8B up 4.4%. Solid Free Cash Flow $10.4B at 16.5% FCF margin, stellar 69.4% Gross margin, 9.8% ROIC, and 66.3% Total Debt to Equity. This educational content positions PFE as a stable pharma giant with pipeline potential for undervalued stocks portfolios.
Key Catalysts
- High 69.4% gross margin driving profitability
- $10.4B FCF supporting dividends and R&D
- Steady 4.4% revenue growth in core pharma
- 9.8% ROIC reflecting efficient operations
Risk Factors
- Recent -1.7% 1Y return from patent cliffs
- Pipeline execution risks in drug development
- Regulatory hurdles for new approvals
- Generic competition pressures
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #6: ConocoPhillips (COP)
| Metric | Value |
|---|---|
| Market Cap | $129.2B |
| Quality Rating | 6.3 |
| Intrinsic Value | $114.4 |
| 1Y Return | 3.6% |
| Revenue | $60.2B |
| Free Cash Flow | $16.6B |
| Revenue Growth | 8.1% |
| FCF margin | 27.6% |
| Gross margin | 30.1% |
| ROIC | 5.4% |
| Total Debt to Equity | 36.2% |
Investment Thesis
ConocoPhillips (COP) in energy features Market Cap $129.2B and Quality rating 6.3. Intrinsic value $114.4 indicates undervaluation, with 3.6% 1Y Return and Revenue $60.2B growing 8.1%. Impressive Free Cash Flow $16.6B at 27.6% FCF margin, 30.1% Gross margin, 5.4% ROIC, and low 36.2% Total Debt to Equity. Analysis reveals COP's disciplined approach in oil & gas for commodity sector exposure.
Key Catalysts
- Strong 27.6% FCF margin and $16.6B cash flow
- 8.1% revenue growth tied to energy demand
- Balanced 36.2% debt supporting acquisitions
- 5.4% ROIC in volatile energy markets
Risk Factors
- Commodity price volatility impacting revenues
- Energy transition pressures on fossil fuels
- Geopolitical supply disruptions
- Modest 3.6% 1Y return variability
Stock #7: Enbridge Inc. (ENB)
| Metric | Value |
|---|---|
| Market Cap | $106.2B |
| Quality Rating | 5.1 |
| Intrinsic Value | $83.5 |
| 1Y Return | 11.4% |
| Revenue | $64.3B |
| Free Cash Flow | $3,965.0M |
| Revenue Growth | 32.6% |
| FCF margin | 6.2% |
| Gross margin | 25.6% |
| ROIC | 5.5% |
| Total Debt to Equity | 159.1% |
Investment Thesis
Enbridge Inc. (ENB), a midstream energy leader, has Market Cap $106.2B and Quality rating 5.1. Intrinsic value $83.5 shows undervaluation, 11.4% 1Y Return, Revenue $64.3B up 32.6%. Free Cash Flow $3,965.0M at 6.2% FCF margin, 25.6% Gross margin, 5.5% ROIC, 159.1% Total Debt to Equity. This frames ENB as a yield-focused pipeline play.
Key Catalysts
- Explosive 32.6% revenue growth from expansions
- Stable 11.4% 1Y return with dividend appeal
- Infrastructure assets driving steady cash flows
- 5.5% ROIC in regulated midstream
Risk Factors
- Elevated 159.1% debt-to-equity ratio
- Regulatory risks to pipeline projects
- Energy demand shifts affecting volumes
- Thin 6.2% FCF margin
Stock #8: United Parcel Service, Inc. (UPS)
| Metric | Value |
|---|---|
| Market Cap | $89.9B |
| Quality Rating | 6.2 |
| Intrinsic Value | $149.5 |
| 1Y Return | -6.2% |
| Revenue | $88.7B |
| Free Cash Flow | $4,765.0M |
| Revenue Growth | (2.6%) |
| FCF margin | 5.4% |
| Gross margin | 27.6% |
| ROIC | 11.3% |
| Total Debt to Equity | 198.6% |
Investment Thesis
United Parcel Service, Inc. (UPS) in logistics holds Market Cap $89.9B, Quality rating 6.2. Intrinsic value $149.5 signals undervaluation, -6.2% 1Y Return, Revenue $88.7B down 2.6%. Free Cash Flow $4,765.0M at 5.4% FCF margin, 27.6% Gross margin, 11.3% ROIC, 198.6% Total Debt to Equity. Analysis spotlights UPS's e-commerce resilience.
Key Catalysts
- $4.8B FCF enabling network investments
- 11.3% ROIC from operational scale
- E-commerce volume growth potential
- 27.6% gross margin stability
Risk Factors
- -6.2% 1Y return from volume slowdowns
- High 198.6% debt amid rate hikes
- Labor and fuel cost inflation
- Competitive pressures in delivery
Stock #9: Elevance Health Inc. (ELV)
| Metric | Value |
|---|---|
| Market Cap | $76.4B |
| Quality Rating | 5.7 |
| Intrinsic Value | $588.8 |
| 1Y Return | -13.1% |
| Revenue | $198.7B |
| Free Cash Flow | $3,174.0M |
| Revenue Growth | 12.4% |
| FCF margin | 1.6% |
| Gross margin | 56.2% |
| ROIC | 24.2% |
| Total Debt to Equity | 2.8% |
Investment Thesis
Elevance Health Inc. (ELV) in healthcare manages Market Cap $76.4B, Quality rating 5.7. Intrinsic value $588.8 indicates major undervaluation, -13.1% 1Y Return, enormous Revenue $198.7B up 12.4%. Free Cash Flow $3,174.0M at 1.6% FCF margin, 56.2% Gross margin, 24.2% ROIC, low 2.8% Total Debt to Equity. Ideal for managed care exposure.
Key Catalysts
- 12.4% revenue growth in health services
- Top-tier 24.2% ROIC efficiency
- Minimal 2.8% debt providing flexibility
- Scale from $198.7B revenue base
Risk Factors
- -13.1% 1Y return from reimbursement pressures
- Slim 1.6% FCF margin vulnerabilities
- Regulatory changes in healthcare
- Membership volatility
Stock #10: CSX Corporation (CSX)
| Metric | Value |
|---|---|
| Market Cap | $69.7B |
| Quality Rating | 5.9 |
| Intrinsic Value | $41.0 |
| 1Y Return | 15.4% |
| Revenue | $15.0B |
| Free Cash Flow | $3,227.0M |
| Revenue Growth | 2.9% |
| FCF margin | 21.6% |
| Gross margin | 36.0% |
| ROIC | 945.2% |
| Total Debt to Equity | 138.0% |
Investment Thesis
CSX Corporation (CSX) in rail transportation has Market Cap $69.7B, Quality rating 5.9. Intrinsic value $41.0 shows undervaluation, 15.4% 1Y Return, Revenue $15.0B up 2.9%. Free Cash Flow $3,227.0M at 21.6% FCF margin, 36.0% Gross margin, extraordinary 945.2% ROIC, 138.0% Total Debt to Equity. Exceptional ROIC underscores rail efficiency.
Key Catalysts
- Outstanding 945.2% ROIC from asset optimization
- 21.6% FCF margin and steady growth
- 15.4% 1Y return in industrials
- Network advantages in freight
Risk Factors
- 138.0% debt-to-equity exposure
- Economic slowdowns hitting volumes
- Fuel and labor cost fluctuations
- Competition from trucking
Portfolio Diversification Insights
This stock watchlist offers balanced diversification: technology (MU, INTC ~28% allocation by market cap), financials (SAN ~10%), industrials/aerospace (BA, CSX ~14%), healthcare (PFE, ELV ~12%), energy/commodities (COP, ENB ~12%), and logistics (UPS ~5%). High-quality leaders like MU complement stable cash generators like COP and PFE, reducing sector-specific risks. Energy and healthcare provide defensive tilts, while tech adds growth. Cross-references show MU's ROIC strength pairing with CSX's efficiency, creating a resilient mix for investment opportunities across cycles.
Market Timing & Entry Strategies
Consider entry on pullbacks to intrinsic value discounts, monitoring quarterly earnings for revenue/FCF beats. Dollar-cost average into high-quality names like MU during tech dips, or energy like COP amid oil stability. Watch macroeconomic signals like interest rates affecting debt-heavy picks (BA, ENB). Use ValueSense tools for backtesting entry points, focusing on 1Y return leaders for momentum while scaling into undervalued laggards like ELV.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Nelson Peltz - Trian Fund Management Portfolio Q3'2025: Top Holdings & Recent Changes
- Principles for Dealing with the Changing World Order by Ray Dalio
- The Ascent of Money by Niall Ferguson
- Principles for Navigating Big Debt Crises by Ray Dalio
- Influence: The Psychology of Persuasion by Robert B. Cialdini Ph.D.
FAQ Section
How were these stocks selected?
These 10 stocks were curated from ValueSense data emphasizing high intrinsic value upside, quality ratings above 5.0 on average, strong FCF where positive, and sector diversity for balanced stock watchlist construction.
What's the best stock from this list?
Micron Technology (MU) leads with the highest Quality rating 8.2, 348.5% 1Y return, and superior metrics like 40.9% FCF margin, making it a standout in this best stocks analysis.
Should I buy all these stocks or diversify?
Diversification across sectors like tech, energy, and healthcare reduces risk; allocate based on portfolio needs rather than concentrating in any single pick from this educational watchlist.
What are the biggest risks with these picks?
Key risks include high debt levels (e.g., BA at 991.4%), negative FCF (INTC), commodity volatility (COP, ENB), and sector-specific headwinds, balanced against strong intrinsic values.
When is the best time to invest in these stocks?
Optimal timing aligns with market dips toward intrinsic values, post-earnings confirmations of growth, or favorable macro shifts like stabilizing rates for debt-laden names.